To make things worse, new therapies targeting the immune- checkpoint such as PD-L1 have no significant effects in clinical research of HCC 5 and the efficacy and applicability of Sorafenib (the only molecular target drug for advanced HCC worldwide) is limited 8. Here, CD274 is linked to hepatocellular carcinoma.